ReproCELL Inc. (4978) AI Stock Analysis

• Market Cap: ¥15.54B
• Dividend Yield: N/A
• Average Volume (3M): 2.34M
• Price to Earnings (P/E): 154.2
• Beta (1Y): 0.65
• Revenue Growth: 8.46%
• EPS Growth: 49.97%
• Country: JP
• Employees: 96
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 1.45
• Shares Outstanding: 94,802,895
• 10 Day Avg. Volume: 2,384,690
• 30 Day Avg. Volume: 2,338,323
• PEG Ratio: -2.80
• Price to Book (P/B): 1.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: ―

ReproCELL Inc.'s overall stock score reflects a company facing significant profitability and cash flow challenges despite revenue growth and a solid balance sheet. Technical indicators are mixed, and the negative valuation metrics further weigh down the score. Strategic improvements in cost management and profitability are crucial for long-term stability.

ReproCELL Inc. Business Overview & Revenue Model

Company Description

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.

How the Company Makes Money

ReproCELL Inc. generates revenue primarily through the sale of its proprietary stem cell products, reagents, and technologies that support drug discovery and regenerative medicine research. The company earns income by providing contract research services to pharmaceutical companies and academic institutions, enabling them to utilize ReproCELL's specialized technologies and expertise. Additionally, the company may form strategic partnerships or collaborations with other biotechnology companies to co-develop products or leverage mutual strengths, contributing to its revenue streams.

ReproCELL Inc. Financial Statement Overview

Summary

ReproCELL Inc. has a mixed financial performance. The company shows a strong gross profit margin and revenue growth, but faces challenges with negative profit margins and cash flow issues. The balance sheet is robust with minimal leverage, but operational inefficiencies and cash flow constraints are significant concerns.

Income Statement

ReproCELL Inc. shows a mixed income statement. Gross profit margin for TTM (Trailing-Twelve-Months) is 52.0%, indicating a solid ability to manage costs relative to revenue. However, the company faces challenges with a negative net profit margin of -4.1% and negative EBIT and EBITDA margins of -11.0% and -8.2% respectively, reflecting operational inefficiencies and high expenses. Revenue growth rate is positive at 12.0% from the previous year, a positive indicator of sales expansion.

Balance Sheet

ReproCELL Inc.'s balance sheet is relatively strong with a high equity ratio of 79.1% in TTM, showcasing financial stability and a low reliance on debt. The debt-to-equity ratio is effectively zero, indicating no leverage risk. However, the company has a negative return on equity (ROE) of -1.2%, indicating inefficiencies in generating profits from shareholders' equity.

Cash Flow

The cash flow statement highlights significant issues with cash generation. The operating cash flow to net income ratio is zero, illustrating an inability to convert income into cash flow. Free cash flow remains negative, and the lack of free cash flow growth is concerning, indicating ongoing operational cash constraints.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
2.72B	2.43B	2.95B	2.23B	1.29B	1.20B
	Gross Profit
1.41B	1.12B	1.14B	803.44M	482.70M	474.71M
	EBIT
-299.97M	-409.29M	-356.22M	-647.13M	-1.05B	-908.94M
	EBITDA
-221.65M	8.24M	-254.59M	-513.85M	-726.20M	-924.65M
	Net Income Common Stockholders
-110.75M	-31.41M	-305.31M	-575.09M	-812.57M	-1.02B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.43B	6.57B	6.38B	4.64B	4.60B	5.19B
	Total Assets
11.23B	9.05B	8.36B	8.10B	6.05B	6.55B
	Total Debt
0.00	0.00	0.00	80.00M	80.00M	80.00M
	Net Debt
-3.80B	-2.94B	-1.91B	-2.56B	-2.52B	-4.51B
	Total Liabilities
2.34B	741.03M	780.63M	844.53M	656.43M	494.89M
	Stockholders Equity
8.89B	8.31B	7.58B	7.25B	5.38B	6.05B
Cash Flow		Free Cash Flow
0.00	-203.88M	-301.57M	-294.27M	-713.15M	-830.63M
	Operating Cash Flow
0.00	-11.45M	-140.53M	-246.24M	-648.88M	-689.80M
	Investing Cash Flow
0.00	404.42M	-1.09B	-2.14B	-1.42B	1.22B
	Financing Cash Flow
0.00	544.05M	482.87M	2.38B	4.41M	6.57M

ReproCELL Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 166.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4978, the sentiment is Positive. The current price of 166 is above the 20-day moving average (MA) of 153.10, above the 50-day MA of 148.42, and above the 200-day MA of 132.65, indicating a bullish trend. The MACD of 5.46 indicates Negative momentum. The RSI at 57.85 is Neutral, neither overbought nor oversold. The STOCH value of 58.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4978.

ReproCELL Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	64 Neutral	¥13.73B	279.66		0.72%	-12.84%	-94.49%
7096	59 Neutral	¥11.98B	30.34		―	7.98%	24.12%
7774	58 Neutral	¥23.76B	―		―	-2.34%	-278.32%
Sector *	53 Neutral	$5.18B	3.30	-45.04%	2.85%	16.82%	-0.65%
7776	53 Neutral	¥18.30B	―		―	-4.04%	-0.88%
4978	49 Neutral	¥15.54B	154.22		―	8.46%	49.97%
4599	47 Neutral	¥19.20B	―		―	-100.00%	-1079.89%